Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Donna Lamb is using her medical education perspective in her latest leadership role, from her job as a critical care nurse to working with doctors to connect nurses who are checking patients on the job during the outbreak.
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal Cancer
2.
An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.
3.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
4.
The most precise research tools for the deadliest blood cancer have been developed.
5.
EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer
1.
The Mystery of Carotid Body Tumors: The Facts You Need to Know
2.
Survival Rates in Cancer: Focus on Acute Myeloid Leukemia and Other Malignancies
3.
From Autoimmune Disorders to COVID-19: How Plasmapheresis Is Revolutionizing Modern Medicine
4.
Leukemia: Understanding the Disease and Its Impact on Patients
5.
Uncovering the Mysteries of Breast Cancer: The Journey to a Cure
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
2.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Navigating the Complexities of Ph Negative ALL - Part X
5.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge